Skip to main content
SpringerLink
Log in

Progressive Systemic Scleroderma

  • Chapter
Autoimmune Diseases of the Skin

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Artlett CM, Smith CB, Jimenez SA (1998) Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 338: 1186–1191

    Article  PubMed  Google Scholar 

  • Badesch D, Tapson VF, McGoon MD (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Int Med 132: 425–434

    PubMed  Google Scholar 

  • Black CM, Silman SJ, Herrick AI (1998) Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double blind, placebo-controlled trial. Arthritis Rheum 42: 299–305

    Article  Google Scholar 

  • Blockmans D, Beyens G, Verhaege R (1996) Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases. Clin Rheumatol 15: 148–153

    PubMed  Google Scholar 

  • Bottomley WW, Goodfield MJ, Sheehan-Dare RA (1996) Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. Br J Dermatol 135: 302–302

    PubMed  Google Scholar 

  • Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM (1998) Anti-RNA Polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 37: 15–20

    Article  PubMed  Google Scholar 

  • Burastero SE, Galbiati S, Vassallo A, Sabbadini MG, Bellone M, Marchionni L et al. (2003) Cellular microchimerism as a lifelong physiologic status in parous women: an immunologic basis for its amplification in patients with systemic sclerosis. Arthiritis Rheum 48: 1109–1116

    Article  Google Scholar 

  • Chang YJ, Spiera H (1999) Renal transplantation in scleroderma. Medicine 78: 382–385

    PubMed  Google Scholar 

  • Clements PJ, Lachenbruch PA, Ng SC (1990) Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 33: 1256–1263

    PubMed  Google Scholar 

  • Clements PJ, Furst DE (1997) Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation. J Rheumatol 24: 85–88

    Google Scholar 

  • Clements PJ, Furst DE, Wong WK (1999) High dose versus low dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two year, double blind, randomized, controlled clinical trial. Arthritis Rheum 42: 1194–203

    Article  PubMed  Google Scholar 

  • Denton CP, Sweny P Abdulla A, Black CM (1994) Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 33: 90–92

    PubMed  Google Scholar 

  • Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ et al. (2002) Deficient Smad 7 expression: aputative molecular defect in scleroderma. PNAS 99: 3908–13

    Article  PubMed  Google Scholar 

  • Duncan MR, Hasan A, Berman B (1995) Pentoxifylline, pentifylline and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 downregulation. J Invest Dermatol 104: 282–286

    Article  PubMed  Google Scholar 

  • Dziadzio M, Denton CP Smith R (1999) Losartan therapy for raynauds phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel group, controlled trial. Arthritis Rheum 42: 2646–2455

    Article  PubMed  Google Scholar 

  • Eckes B, Mauch C, Huppe G, Krieg T (1996) Differential regulation of transcription and transcript stability of pro a1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic sclerosis. Biochem J 315: 549–553

    PubMed  Google Scholar 

  • Enomoto, Mekkes JR, Bossuyt PM (1999) Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 41: 915–922

    PubMed  Google Scholar 

  • Evans PC, Lambert N, Maloney S (1999) Long term fetal microchimerism in peripheral blood mononuclear scell subsets in healthy women and women with scleroderma. Blood 93: 2033–2037

    PubMed  Google Scholar 

  • Fritzler MJ (1993) Autoantibodies in scleroderma. J Dermatol 20: 257–268

    PubMed  Google Scholar 

  • Furst DE, Clements PJ, Steen VD (1998) The modified rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25: 84–88

    PubMed  Google Scholar 

  • Genth E, Mierau R, Genetzky P (1990) Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum 33: 657–665

    PubMed  Google Scholar 

  • Jablonska S, Blaszyk M (1999) Scleroderma Overlap Syndromes. Adv Exp Med Biol 455: 85–92

    PubMed  Google Scholar 

  • Janowsky EC, Kupper LL, Hulka BS (2000) Meta-analyses of the relation between silicone breast implants and the risk of connective tissue. N Engl J Med 342: 781–790

    Article  PubMed  Google Scholar 

  • Haustein UF, Anderegg U (1998) Silica induced scleroderma — clinical and experimental aspects. J Rheumatol 25: 1917–1926

    PubMed  Google Scholar 

  • Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43: 889–93

    Article  PubMed  Google Scholar 

  • Heickendorff L, Zachariae H, Bjerring P, Halkier-Sorensen L, Sondergaard K (1995) The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. J Am Acad Dermatol 32: 584–588

    Article  PubMed  Google Scholar 

  • Herrmann K, Heckmann M, Kulozik M, Haustein UF, Krieg T (1991) Steady state mRNA levels of collagens I,III, fibronectin and collagenase in skin biopsies of systemic sclerosis patients. J Invest Dermatol 97: 219–225

    Article  PubMed  Google Scholar 

  • Herrmann G, Wlaschek M, Lange TS, Prenzel K, Goerz G, Scharffetter-Kochanek K (1993) UVA irradiation stimulates the synthesis of various matrix-metalloproteinases (MMPs) in cultured human fibroblasts. Exp Dermatol 2: 92–97

    PubMed  Google Scholar 

  • Hoeper MM et al. (2000) Long term treatment of primary pulmonary hypertension with aerolized iloprost, a prostacyclin analogue. N Engl J Med 342: 1866–70

    Article  PubMed  Google Scholar 

  • Hunzelmann N, Anders S, Fierlbeck G, Hein R, Herrmann K, Albrecht M, Bell S, Thur J, Muche R, Adelmann-Grill B, Wehner-Caroli J, Gaus W, Krieg T (1997) Systemic scleroderma: multicenter trial of one year treatment with recombinant interferon-gamma. Arch Dermatol 133: 609–613

    Article  PubMed  Google Scholar 

  • Hunzelmann N, Risteli J, Risteli L, Sacher C, Black CM, Krieg T (1998a) Increased circulating concentrations of the type I collagen specific degradation product ICTP in systemic sclerosis reflect the extent of skin involvement: A new serum marker for clinical severity in SSc patients. Br J Dermatol 139: 1020–1025

    Article  PubMed  Google Scholar 

  • Hunzelmann N, Scharfetter-Kochanek K, Hager C, Krieg T (1998b) Management of localized scleroderma. Sem Cutan Med Surg 17: 34–41

    Google Scholar 

  • Igarashi A, Nashiro K, Kikuchi K (1995) Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 105: 280–284

    Article  PubMed  Google Scholar 

  • Jimenez SA and Saitta B (2000) Alterations in the regulation of expression of the a1(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma). Springer Semin Immunopathol 21: 397–414

    Google Scholar 

  • Kahaleh MB, Sultany GL, Smith EA, Huffstetter JE, Loadholt CB, LeRoy EC (1986) A modified scleroderma skin scoring method. Clin Exp Rheumatol 4: 367–369

    PubMed  Google Scholar 

  • Kahaleh M, Fan PS (1997) Mechanism of serum mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 83: 32–40

    Article  PubMed  Google Scholar 

  • Kerscher M, Meurer M, Sander C, Volkenandt M, Lehmann P, Plewig G, Röcken M (1996) PUVA bath photochemotherapy for localized scleroderma. Arch Dermatol 132: 1280–1282

    Article  PubMed  Google Scholar 

  • Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T (1990) Co-localization of transforming growth factor ß2 with al(1) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 86: 917–921

    PubMed  Google Scholar 

  • LeRoy EC (1974) Increased collagen synthesis by scleroderma fibroblasts in vitro. J Clin Invest 54: 880–889

    PubMed  Google Scholar 

  • Lunardi C (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nature Med 6: 1183–1186

    Article  PubMed  Google Scholar 

  • Majewski S, Hunzelmann N, Johnson JP, Jung C, Mauch C, Ziegler-Heitbrock H, Riethmüller G, Krieg T (1991) Expression of intercellular adhesion molecule-1 (ICAM-1) on fibroblasts in the skin of patients with systemic sclerosis. J Invest Dermatol 97: 667–671

    Article  PubMed  Google Scholar 

  • Marguerie C (1992) The clinical and immunogenetic features of patients with autoantibodies to the nucleolar anitgen PM-Scl. Medicine 71: 327–336

    PubMed  Google Scholar 

  • Maricq H, LeRoy E, Dangelo W (1980) Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23: 183–189

    PubMed  Google Scholar 

  • Mauch C (1998) Regulation of connective tissue turnover by cell-matrix interactions. Arch Dermatol Res 290: S30–36

    PubMed  Google Scholar 

  • McCormick LL, Zhang Y, Tootell E, Gilliam AC (1999) Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 163: 5693–5699

    PubMed  Google Scholar 

  • McKown KM, Carbone LD, Bustillo J (2000) Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 43: 1054–1061

    Article  PubMed  Google Scholar 

  • Perlish JS, Lemlich G, Fleischmajer R (1988) Identification of collagen fibrils in scleroderma skin. J Invest Dermatol 90: 48–54

    Article  PubMed  Google Scholar 

  • Pigula FA, Griffith BP, Zenati MA (1997) Lung transplantation for respiratory failure resulting from systemic disease. Ann Thorac Surg 64: 1630–1634

    Article  PubMed  Google Scholar 

  • Poormoghim H, Lucas M, Fertig N, Medsger TA (2000) Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty eight patients. Arthritis Rheum 43: 444–451

    Article  PubMed  Google Scholar 

  • Pope J, Bellamy N, Seibold J (1998) A controlled trial of methotrexate versus placebo in early diffuse scleroderma — preliminary analysis. Arthritis Rheum 41: S420

    Google Scholar 

  • Pope J, Fenlon D, Thompson A (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2: CD000953

    PubMed  Google Scholar 

  • Prescott RJ, Freemont A, Jones C (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166: 255–263

    PubMed  Google Scholar 

  • Rook AH, Freundlich B, Jegasothy BV (1992) Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol 128: 337–346

    Article  PubMed  Google Scholar 

  • Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM et al. (2002) Bosentan therapy for pulmonary hypertension. NEJM 346: 896–903

    Article  PubMed  Google Scholar 

  • Scharffetter K, Lankat-Buttgereit B, Krieg T (1988) Localization of collagen mRNA in normal and scleroderma skin by in situ hybridization. Eur J Clin Invest 18: 9–17

    PubMed  Google Scholar 

  • Scharffetter K, Wlaschek M, Hogg A, Bolsen K, Schothorst A, Goerz G, Krieg T, Plewig G (1991) UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 283: 506–511

    Article  PubMed  Google Scholar 

  • Seibold J (1994) Systemic sclerosis. In: Klipped J, Dieppe P, Mosby St. Louis (Eds) Rheumatology, 8.1–8.14

    Google Scholar 

  • Seibold J, Korn J, Simms R (2000) Recombinant human relaxin in the treatment of scleroderma. A randomized, double blind, placebo-controlled study. Ann Int Med 132: 871–879

    PubMed  Google Scholar 

  • Sgonc R, Gruschwitz M, Dietrich H (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98: 785–792

    PubMed  Google Scholar 

  • Shi-Wen X, Pennington D, Holmes A (2000) Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 25: 213–224

    Article  Google Scholar 

  • Sjogren RW (1996) Gastrointestinal features of scleroderma. Curr Opin Rheumatol 8: 569–575

    PubMed  Google Scholar 

  • Steen VD, Constantino JP, Shapiro AP, Medsger TA (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Int Med 113: 352–357

    PubMed  Google Scholar 

  • Steen VD, Follansbee WP, Conte CG, Medsger TA (1996) Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum 39: 677–681

    PubMed  Google Scholar 

  • Steen VD, Medsger TA (1998) Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41: 1613–1619

    Article  PubMed  Google Scholar 

  • Stege H, Berneburg M, Humke S (1997) High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 36: 938–944

    PubMed  Google Scholar 

  • Stone PJ, Korn JH, North H, Lally EV, Miller LC, Tucker LB, Strongwater S, Snider GL, Franzblau C (1995): Cross-linked elastin and collagen degradation products in the urine of patients with scleroderma. Arthritis Rheum 38: 517–524

    PubMed  Google Scholar 

  • Straniero NR, Furst DE (1989) Environmentally induced systemic sclerosis like illness. Baillieres Clin Rheumatol 3: 63–79

    PubMed  Google Scholar 

  • Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnosis and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581–590

    Google Scholar 

  • Tyndall A, Black C, Finke J, Peter H, Gratwohl A (1997) Treatment of systemic sclerosis with autologous hemopoetic stem cell transplantation. The Lancet 349: 254–356

    Article  Google Scholar 

  • Uitto J, Bauer EA, Eisen AZ (1979) Scleroderma. Increased biosynthesis of triple helical type I and type III procollagen associated with unaltered expression of collagenase by skin fibroblasts in culture. J Clin Invest 64: 921–930

    PubMed  Google Scholar 

  • van den Hoogen FH, Boerbooms AM, Swaak AJ (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double blind trial, followed by a 24 week observation trial. Br J Rheumatol 35: 364–372

    PubMed  Google Scholar 

  • White B, Bauer EA, Goldsmith LA (1995) Guidelines for clinical trials in systemic sclerosis (scleroderma). I. disease modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic sclerosis. Arthritis Rheum 38: 351–360

    PubMed  Google Scholar 

  • White B, Moore WC, Wigley FM (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Int Med 132: 947–954

    PubMed  Google Scholar 

  • Williams HJ, Alarcon GS, Joks R (1999) Early undifferentiated connective tissue disease. VI an inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 26: 816–825

    PubMed  Google Scholar 

  • Zachariae H, Halkier-Sorensen L, Bjerring P, Heickendorff L (1996) Treatment of ischemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis. Acta Derm Venereol 76: 236–238

    PubMed  Google Scholar 

Download references

Authors
  1. Nicolas Hunzelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Krieg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology and Allergology, Philipps University, Marburg, Germany

    Michael Hertl MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Wien

About this chapter

Cite this chapter

Hunzelmann, N., Krieg, T. (2005). Progressive Systemic Scleroderma. In: Hertl, M. (eds) Autoimmune Diseases of the Skin. Springer, Vienna. https://doi.org/10.1007/3-211-27377-8_8

Download citation

  • DOI: https://doi.org/10.1007/3-211-27377-8_8

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-20686-7

  • Online ISBN: 978-3-211-27377-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation